Biomea Fusion Price to Free Cash Flow Ratio 2020-2024 | BMEA

Biomea Fusion price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as

Biomea Fusion Price to Free Cash Flow Ratio 2020-2024 | BMEA

Biomea Fusion price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$172.8B
Vertex Pharmaceuticals (VRTX)$125.8B
Regeneron Pharmaceuticals (REGN)$111.1B
Bristol Myers Squibb (BMY)$108.2B
Gilead Sciences (GILD)$108B
CSL (CSLLY)$97B
GSK (GSK)$81.3B
Alnylam Pharmaceuticals (ALNY)$38.6B
Argenex SE (ARGX)$32.3B
BioNTech SE (BNTX)$28B
Biogen (BIIB)$27.5B
Illumina (ILMN)$22.9B
Moderna (MRNA)$22.1B
BeiGene (BGNE)$21.6B
Genmab (GMAB)$15B
BioMarin Pharmaceutical (BMRN)$13.3B
Insmed (INSM)$13.2B
Vaxcyte (PCVX)$13.2B
Exact Sciences (EXAS)$13B
Incyte (INCY)$12.7B
Sarepta Therapeutics (SRPT)$12B
Bio-Techne Corp (TECH)$11.4B
QIAGEN (QGEN)$9.9B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.9B
Revolution Medicines (RVMD)$8.4B
Exelixis (EXEL)$8.4B
Intra-Cellular Therapies (ITCI)$8B
Legend Biotech (LEGN)$8B
Ascendis Pharma (ASND)$7.9B